RGPX · As filed with the SEC

Regenerex Pharma cash flow statement, by quarter

The statement as Regenerex Pharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

STATEMENTS OF CASH FLOWS · USD

USD	Q2 FY25^† 3 months ended Sep 30, 2025	Q1 FY24 3 months ended Jun 30, 2025	Q4 FY24^† 3 months ended Mar 31, 2025	Q3 FY24^† 3 months ended Dec 31, 2024	Q2 FY24^† 3 months ended Sep 30, 2024	Q1 FY24 3 months ended Jun 30, 2024	Q4 FY23^† 3 months ended Mar 31, 2024	Q3 FY23^† 3 months ended Dec 31, 2023
Cash Flows from Operating Activities:
Net Income (Loss)	(814,012)^†	(663,584)	(1,410,385)^†	(314,524)^†	(529,572)^†	(272,560)	(292,827)^†	(263,976)^†
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation Expense	1,157^†	1,259	426^†	643^†	841^†	1,144	1,145^†	1,158^†
Foreign currency adjustment	539^†	6,092	17,294^†	(24,000)^†	5,031^†	(4,053)	(9,629)^†	4,373^†
Stock-Based Compensation Expense	177,867^†	257,133	57,894^†	17,973^†	35,798^†	20,997	57,064^†	21,246^†
Research and Development Expense	—	—	—	—	—	—	0^†	—
Purchase of Intangible Assets	—	—	—	—	—	—	0^†	0^†
Non-cash extension fee to Greenwich Resources	—	—	—	0^†	—	—	—	—
Net Cash from Operating Activities	—	—	(3,349)^†	(3,348)^†	(2,548)^†	29,052	12,469^†	18,370^†
Amortization of ROU assets, net of liabilities	(3,348)^†	(13,348)	—	—	(2,548)^†	—	—	—
Changes in operating assets and liabilities:
Prepaid expenses	(16,520)^†	(19,900)	300^†	891^†	816^†	183	(1,117)^†	11,827^†
Change in Accounts Payable	—	—	—	—	—	—	—	107,175^†
Accounts payable	47,481^†	(26,405)	66,608^†	51,221^†	6,786^†	63,300	57,551^†	9,097^†
Accrued compensation	(54,593)^†	20,250	40,118^†	96,885^†	96,885^†	96,885	96,885^†	96,885^†
Other accrued liabilities	142,074^†	(39,440)	(53,606)^†	15,546^†	19,357^†	9,720	14,024^†	1,193^†
Net Cash from Operating Activities	(519,355)^†	(477,943)	(1,284,700)^†	(158,713)^†	(126,606)^†	(55,332)	(64,435)^†	(99,827)^†
Purchase of furniture and computer equipment	—	—	—	—	—	—	0^†	0^†
Net Cash from Investing Activities	—	—	—	—	—	—	0^†	0^†
Proceeds from Debt Issuance	—	—	3,805^†	—	—	1,600	(1,067)^†	2,120^†
Net Cash from Financing Activities	—	—	—	—	—	—	0^†	—
Repayment of notes payable to related parties	(87,498)^†	(17,652)	—	—	—	—	—	(5,500)^†
Other Affiliates	—	—	—	—	—	—	6,670^†	36,826^†
Affiliated Entity	—	—	568,920^†	—	—	53,360	225,000^†	—
Payments of notes payable to shareholders	—	—	—	—	—	—	0^†	0^†
Net Cash from Financing Activities	—	—	—	—	—	—	(8,000)^†	—
Proceeds from notes payable to related parties	—	—	—	—	78,500^†	—	—	—
Proceeds from Stock Issuance	485,000^†	15,000	2,250,000^†	0^†	—	—	50,000^†	0^†
Net cash provided by financing activities	397,502^†	(2,652)	1,938,615^†	158,757^†	126,900^†	54,960	56,951^†	101,603^†
Net Change in Cash	(160,771)^†	(480,595)	652,687^†	44^†	294^†	(372)	(7,484)^†	1,776^†
Cash and cash equivalents, beginning of period	172,430	653,025	338	294	0	372	7,856	6,080
Cash and cash equivalents, end of period	11,659	172,430	653,025	338	294	—	372	7,856
Accrued interest converted into note payable to shareholder	11,688^†	11,779	43,511^†	12,059^†	12,358^†	14,264	20,271^†	73,095^†
Accrued interest converted into note payable to related parties	6,420^†	7,211	11,469^†	7,686^†	750^†	4,866	0^†	1^†
Operating lease, ROU asset and liabilities	—	—	0^†	—	—	—	(180)^†	0^†
Note payable issued for research and development	—	—	—	—	—	—	0^†	0^†
Note payable for interest expense	—	—	—	0^†	—	—	—	—
Non-Cash Investing and Financing	41,613^†	18,990	—	—	253,148^†	—	—	—

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.